STAT

A rhyming year in review: Limericks that capture the best and worst of life sciences in 2017

There once was a poet from STAT/Who pulled fun rhymes out of a hat/Her limericks made us laugh/And her every paragraph/Is a gift we hope doesn't fall flat.

We’re big fans of the offbeat here at STAT. So what better way to round out the last days of 2017 than to bring you the year in review — in rhyme? Without further ado, to see last year’s offerings.) 

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks